TY  - CHAP
M1  - Book, Section
TI  - Systemic Chemotherapy for Mesothelioma
A1  - Rohs, Nicholas
A1  - Jackman, David M.
A1  - Ciofreddi, Leigh-Anne
A1  - Gomez, Jorge E.
A2  - Sugarbaker, David J.
A2  - Bueno, Raphael
A2  - Burt, Bryan M.
A2  - Groth, Shawn S.
A2  - Loor, Gabriel
A2  - Wolf, Andrea S.
A2  - Williams, Marcia
A2  - Adams, Ann
Y1  - 2020
N1  - 
T2  - Sugarbaker’s Adult Chest Surgery, 3e
AB  - Mesothelioma  is  a  rare,  aggressive  malignancy  arising  from  the  mesothelial  surfaces  of  the  pleura,  peritoneum,  pericardium,  or  tunica  vaginalis.  Incidence  of  the  disease  peaked  in  the  United  States  in  the  mid-1990s  with  approximately  2500  to  3000  new  cases  diagnosed  annually.  However,  its  incidence  in  many  other  parts  of  the  world,  particularly  in  rapidly  industrializing  regions  without  sufficient  asbestos  regulation,  will  continue  to  rise  over  the  next  few  decades.1  Despite  attempts  at  aggressive  multimodality  therapy  for  seemingly  localized  disease,  prognosis  for  mesothelioma  continues  to  be  dismal,  with  median  overall  survival  of  approximately  1  year.2  Since  its  updated  indication  in  2004,  pemetrexed  remains  the  only  chemotherapy  specifically  approved  by  the  U.S.  Food  and  Drug  Administration  (FDA)  for  the  treatment  of  mesothelioma.  Considering  the  high  rates  of  disease  recurrence  or  progression,  the  development  of  effective  systemic  treatment  options  for  mesothelioma  is  sorely  needed.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesssurgery.mhmedical.com/content.aspx?aid=1170414043
ER  -